The lower yield from the first engineering run will impact the timing of the
subsequent GLP (Good Laboratory Practice) toxicology studies, which, in turn, will impact on the
initiation of the planned first human study of PAT-DX1. I
The domino effect is here now for all to see
This six month delay will impact the timing of the first in human study of PAT-DX1, which is now
planned for mid-2023.
Ann: PAT-DX1 engineering update, page-2
-
- There are more pages in this discussion • 175 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
-0.001(12.5%) |
Mkt cap ! $14.40M | |||
| Open | High | Low | Value | Volume |
| 0.7¢ | 0.7¢ | 0.7¢ | $43.28K | 6.183M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 237374 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.8¢ | 1732079 | 8 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| PAB (ASX) Chart |